Integra Lifesciences Holdings (IART) EBT Margin (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of EBT Margin data on file, last reported at 0.61% in Q1 2026.

• For the quarter ending Q1 2026, EBT Margin rose 723.0% year-over-year to 0.61%; the trailing twelve-month figure through Mar 2026 stood at 32.59% (down 2994.0% YoY), and the FY2025 full-year result was 34.46%, down 3333.0% from the prior year.
• EBT Margin slipped to 0.61% in Q1 2026, from 0.99% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 16.13% in Q4 2022 to a low of 127.75% in Q2 2025.
• A 5-year average of 3.91% and a median of 1.0% in 2023 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin plunged 12412 bps in 2025 and jumped 723 bps in 2026, its largest moves.
• Tracing IART's EBT Margin over 5 years: stood at 16.13% in 2022, then sank by 55 bps to 7.27% in 2023, then declined by 30 bps to 5.09% in 2024, then slumped by 81 bps to 0.99% in 2025, then tumbled by 162 bps to 0.61% in 2026.
• Business Quant data shows IART's EBT Margin at 0.61% in Q1 2026, 0.99% in Q4 2025, and 1.7% in Q3 2025.